
|Videos|March 14, 2019
Highlighting CAR T Cell Options for Relapsed/Refractory DLBCL
Author(s)David Miklos, MD
David Miklos, MD, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma.
David Miklos, MD, associate professor of medicine at Stanford University, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma (DLBCL).
Miklos says it is important to know that chimeric antigen receptor (CAR) T cells are effective and available for patients with relapsed/refractory DLBCL.



















